Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 1, 2016, Pages 105-113

  Bergsbaken, J J ^a   Eickhoff, J C ^b   Buss, B A ^c   Mably, M S ^a   Kolesar, J M ^c  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adherence reporting; Oncology clinical trials; Oral anticancer agents

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CLINICAL TRIAL (TOPIC); HEMATOLOGY; HUMAN; MEDICATION COMPLIANCE; ONCOLOGY; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; ADULT; AGED; DIET THERAPY; FEMALE; MALE; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84960934343     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214567163     Document Type: Review

References (19)

1. Wood L. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 2012; 16: 432-438.
2. Bassan F, Peter F, Houbre B, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 2014; 23: 22-35.
3. Bartel SB. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm 2007; 64(9 Suppl 5): S8-S14.
4. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388.
5. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99: 1763-1768.
6. Osterberg L and Blaschke T. Adherence to medication. NEJM 2005; 353: 487-497.
7. Ebrahim S. Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technol Assess 1998; 11: 1-78.
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
9. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7: 99-108.
10. Schulz KF, Altman DG and Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-732.
11. Gossec L, Tubach F, Dougados M, et al. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci 2007; 334: 248-254.
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
13. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goser-elin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012; 13: 345-352.
14. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996; 347: 363-366.
15. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641.
16. Paterson AH, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.
17. Geynisman DM and Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med 2013; 83: 231-241.
18. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tam-oxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513-529.
19. Lee KP, Schotland M, Bacchetti P, et al. Association of journal quality indicators with methodological quality of clinical research articles. JAMA 2002; 287: 2805-2808.